Overview

Pentoxifylline as Adjunctive Therapy in Patients With Ulcerative Colitis

Status:
Not yet recruiting
Trial end date:
2025-02-20
Target enrollment:
Participant gender:
Summary
The exact underlying mechanisms of ulcerative colitis (UC), an idiopathic, chronic inflammatory disease marked by diffused inflammation of the colon and rectum mucosa, are still unknown. Due to genetic, immune, and environmental factors, UC is highly dependent on cellular immune reactions and exaggerated inflammatory responses. The release of several cytokines, kinins, leukotrienes, platelet-activating factor (PAF), and reactive oxygen species is connected to immunological activity (ROS). Additionally, many of the cytokines will start an acute phase response, making the inflammation worse.
Phase:
Phase 2
Details
Lead Sponsor:
Tanta University
Treatments:
Pentoxifylline